EDAP TMS S.A.

NasdaqGM EDAP

EDAP TMS S.A. EPS (Diluted) for the year ending December 31, 2023: USD -0.63

EDAP TMS S.A. EPS (Diluted) is USD -0.63 for the year ending December 31, 2023, a -589.35% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • EDAP TMS S.A. EPS (Diluted) for the year ending December 31, 2022 was USD -0.09, a -457.92% change year over year.
  • EDAP TMS S.A. EPS (Diluted) for the year ending December 31, 2021 was USD 0.03, a 135.68% change year over year.
  • EDAP TMS S.A. EPS (Diluted) for the year ending December 31, 2020 was USD -0.07, a -225.10% change year over year.
  • EDAP TMS S.A. EPS (Diluted) for the year ending December 31, 2019 was USD 0.06, a 526.59% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
SV Wall Street
NasdaqGM: EDAP

EDAP TMS S.A.

CEO Mr. Ryan Rhodes
IPO Date Aug. 1, 1997
Location France
Headquarters Parc d’Activites la Poudrette-Lamartine
Employees 307
Sector Technology
Industries
Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Similar companies

HSIC

Henry Schein, Inc.

USD 81.91

1.65%

MCK

McKesson Corporation

USD 606.90

0.59%

CAH

Cardinal Health, Inc.

USD 127.45

1.82%

ZYXI

Zynex, Inc.

USD 7.99

-0.87%

PDCO

Patterson Companies, Inc.

USD 31.01

0.03%

OMI

Owens & Minor, Inc.

USD 8.90

-2.63%

StockViz Staff

February 6, 2025

Any question? Send us an email